5 selected, source-linked Epitalon records carrying a 2026 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.
PeptideScanner retained PubMed bibliographic metadata for PMID 40493162 at 2026-07-30T16:14:11.014Z. PubMed recorded a metadata revision date of 2026-06-13 and an Entrez history date of 2025-06-10. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 41240216 at 2026-07-30T16:20:41.667Z. PubMed recorded a metadata revision date of 2026-05-20 and an Entrez history date of 2025-11-15. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.
The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.
PeptideScanner retained PubMed bibliographic metadata for PMID 12209581 at 2026-07-30T16:30:44.156Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2002-09-05. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.